Abstract Library

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study

Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steyn R

Authors: Steyn R, Prasad V,

Keywords: 68Ga DOTANOC PET CT, PGL, PCC,

#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Fahlenkamp U, Prasad V, Pavel M, Geisel D,

Keywords: magnetic resonance, hepatocyte specific, liver specific, gadoxetate, gadoxetic acid, neuroendocrine, staging, shuttle, large bore, whole abdomen, pelvis, extrahepatic evaluation,

#1833 Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder

Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Steyn R, Prasad V,

Keywords: SDHB, Bladder PGL, PRRT ,

#1808 Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study

Introduction: PRRT has potential to control progressive NETs and has been used in combination with somatostatin analogues such as LAN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Prasad V, Truong Thanh X, Houchard A, Bodei L,

Keywords: PRRT, lanreotide,